Levin Capital Strategies L.P. cut its holdings in shares of Maplebear Inc. (NASDAQ:CART – Free Report) by 50.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,250 shares of the company’s stock after selling 14,250 shares during the period. […]
Maplebear (NASDAQ:CART – Free Report) had its price objective upped by Oppenheimer from $36.00 to $48.00 in a research note published on Monday, Benzinga reports. They currently have an outperform rating on the stock. Several other equities analysts have also recently commented on CART. JPMorgan Chase & Co. boosted their price objective on shares of […]
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced.
Maplebear (NASDAQ:CART) Receives Neutral Rating from Moffett Nathanson themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.